North Carolina-based Sprout received the nod Tuesday from the US Food and Drug Administration for flibanserin, to be marketed as Addyi in the United States, to treat a condition known as "acquired, generalized hypoactive sexual desire disorder [HSDD]," or sudden and severe loss of libido.

It was the first FDA-approved treatment for sexual desire disorders in men or women.

Under the terms of the acquisition agreement, Valeant will pay about US$1 billion in cash for Sprout: $500 million upon the closing of the transaction, expected by end-September, and $500 million payable in the first quarter of 2016.

Montreal-based Valeant also will pay a share of future profits benchmarked to achievement of certain milestones.

Valeant expects Addyi to be available in the United States in the fourth quarter this year, and plans to bring the drug to the international market.

"Delivering a first-ever treatment for a commonly reported form of female sexual dysfunction gives us the perfect opportunity to establish a new portfolio of important medications that uniquely impact women," said J. Micheal Pearson, Valeant chairman and chief executive, in a statement.

"We applaud the efforts of the Sprout team to address this important area of unmet need and look forward to working with them to bring the benefits of Addyi to additional markets around the world."

Valeant shares were up 0.2 percent at $245.47 in pre-market trade on the New York Stock Exchange.

Popular

Power begins to return after outage in Indonesia's Bali island

The fragile promise of pluralism, religious freedom in Southeast Asia

Coffee, gold push up inflation to 1.95 percent in April